clinical trial · NCT07494435
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Zhejiang Haichang Biotech Co., Ltd.·phase2·not yet recruiting·n = 230
Hepato Cellular Carcinoma (HCC)Renal Cell CancerWGI-0301Nivolumab (240 mg)WGI-0301
brief summary
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.
started
Jun 1, 2026
primary completion
Jun 1, 2028
completion
Sep 1, 2028
last updated
Mar 27, 2026
official title
An Open-Label Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma or Advance Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol